CN109890393A - 功能rna和小分子药物治疗性复合物和纳米颗粒递送媒介 - Google Patents

功能rna和小分子药物治疗性复合物和纳米颗粒递送媒介 Download PDF

Info

Publication number
CN109890393A
CN109890393A CN201780061209.0A CN201780061209A CN109890393A CN 109890393 A CN109890393 A CN 109890393A CN 201780061209 A CN201780061209 A CN 201780061209A CN 109890393 A CN109890393 A CN 109890393A
Authority
CN
China
Prior art keywords
molecule
cell
small
composition
rna molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780061209.0A
Other languages
English (en)
Chinese (zh)
Inventor
O·K·哈法尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eos Biosciences Co
Original Assignee
Eos Biosciences Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eos Biosciences Co filed Critical Eos Biosciences Co
Publication of CN109890393A publication Critical patent/CN109890393A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780061209.0A 2016-10-03 2017-10-03 功能rna和小分子药物治疗性复合物和纳米颗粒递送媒介 Pending CN109890393A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403595P 2016-10-03 2016-10-03
US62/403,595 2016-10-03
PCT/US2017/054884 WO2018067526A1 (en) 2016-10-03 2017-10-03 Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles

Publications (1)

Publication Number Publication Date
CN109890393A true CN109890393A (zh) 2019-06-14

Family

ID=61831202

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780061209.0A Pending CN109890393A (zh) 2016-10-03 2017-10-03 功能rna和小分子药物治疗性复合物和纳米颗粒递送媒介

Country Status (7)

Country Link
US (1) US20190240344A1 (enExample)
EP (1) EP3518939A4 (enExample)
JP (1) JP2019529571A (enExample)
CN (1) CN109890393A (enExample)
AU (1) AU2017339456A1 (enExample)
CA (1) CA3039040A1 (enExample)
WO (1) WO2018067526A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
MX381016B (es) 2014-01-17 2025-03-12 Cedars Sinai Medical Center Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.
MX2020006890A (es) * 2018-01-02 2020-09-07 Cedars Sinai Medical Center Nanoparticulas para la administracion dirigida de polipeptidos terapeuticos.
CN109432430B (zh) * 2018-11-22 2021-12-17 华南理工大学 一种siRNA和抗癌药物疏水性复合物及其制备方法与应用
JP7698252B2 (ja) * 2019-09-06 2025-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 治療薬の核酸媒介性送達

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506417A (ja) * 1999-08-09 2003-02-18 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
US20120004181A1 (en) * 2009-01-23 2012-01-05 Cedars-Sinai Medical Center Targeted delivery system
WO2017205764A1 (en) * 2016-05-27 2017-11-30 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029212A2 (en) * 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
JP5252618B2 (ja) * 2007-10-26 2013-07-31 独立行政法人産業技術総合研究所 ＲＮＡ干渉効果が高い芳香環修飾ｓｉＲＮＡ
MX381016B (es) * 2014-01-17 2025-03-12 Cedars Sinai Medical Center Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506417A (ja) * 1999-08-09 2003-02-18 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
US20120004181A1 (en) * 2009-01-23 2012-01-05 Cedars-Sinai Medical Center Targeted delivery system
WO2017205764A1 (en) * 2016-05-27 2017-11-30 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAGALKOT, V ET AL: "An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform", 《ANGEW. CHEM. INT. ED.》 *
CHOUDHURY, A ET AL: "Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines", 《INT. J. CANCER》 *
KYOUNGIN MIN ET AL: "Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers", 《BIOMATERIALS》 *

Also Published As

Publication number Publication date
CA3039040A1 (en) 2018-04-12
WO2018067526A1 (en) 2018-04-12
US20190240344A1 (en) 2019-08-08
EP3518939A1 (en) 2019-08-07
JP2019529571A (ja) 2019-10-17
EP3518939A4 (en) 2020-06-24
AU2017339456A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
Guo et al. ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer
Tian et al. JQ1-loaded polydopamine nanoplatform inhibits c-MYC/programmed cell death ligand 1 to enhance photothermal therapy for triple-negative breast cancer
Niu et al. Transdermal gene delivery by functional peptide-conjugated cationic gold nanoparticle reverses the progression and metastasis of cutaneous melanoma
Zhou et al. Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy
CN104428005B (zh) 用于反义寡核苷酸递送的脂质纳米颗粒组合物
Joshi et al. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression
US20250255978A1 (en) Drug-delivery nanoparticles and treatments for drug-resistant cancer
CN109890393A (zh) 功能rna和小分子药物治疗性复合物和纳米颗粒递送媒介
CN111733139B (zh) 一种基于功能化巨噬细胞/单核细胞的靶向递送系统及其构建与应用
Khare et al. Targeted drug delivery systems for pancreatic cancer
CN1798545A (zh) 改良脂质体复合物的稳定性和保存期的方法
Tang et al. A blood–brain barrier-and blood–brain tumor barrier-penetrating siRNA delivery system targeting gliomas for brain tumor immunotherapy
US11110168B2 (en) Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
Silvestre et al. Monoclonal antibodies carried in drug delivery nanosystems as a strategy for cancer treatment
CN107735079A (zh) 核酸‑阳离子聚合物组合物及其制备和使用方法
Bottini et al. Targeted nanodrugs for cancer therapy: prospects and challenges
Chen et al. Activated T cell-derived exosomes for targeted delivery of AXL-siRNA loaded paclitaxel-poly-L-lysine prodrug to overcome drug resistance in triple-negative breast cancer
KR20120026897A (ko) 전하결합 및 생분해성 공유결합으로 동시에 연결된 고분자?ｓｉＲＮＡ 나노입자 전달체
CN103655475B (zh) 靶向的脂质体
KR102228271B1 (ko) 항암활성을 갖는 면역조절 단백질-siRNA 복합체
Ning et al. Gene reprogramming armed macrophage membrane-camouflaged nanoplatform enhances bionic targeted drug delivery to solid tumor for synergistic therapy
Chen et al. Ultrasound-propelled liposome circumvention and siRNA silencing reverse BRAF mutation-arised cancer resistance to trametinib
Li et al. Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review
Pircalabioru et al. Nanodrug delivery systems in cancer
Keyvani et al. Insight into RNA-based Therapies for Ovarian Cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190614

WD01 Invention patent application deemed withdrawn after publication